VBL Therapeutics Files for $75M IPO On Nasdaq

June 9, 2014 | According to a “Globes” report, VBL Therapeutics (formerly known as Vascular Biogenics) announced that it will file for a $75 million initial public offering (IPO) on Nasdaq. The company will reportedly also offer an option for underwriter overallotment, or the issuing of 15 percent more shares, for the underwriters Deutsche Bank Securities, Wells Fargo, JP Morgan and Oppenheimer. Founded in 2000, VBL Therapeutics is developing drugs for the treatment of brain cancer and inflammatory diseases and has raised $100 million in investments.